vs

Side-by-side financial comparison of Doximity, Inc. (DOCS) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.

Doximity, Inc. is the larger business by last-quarter revenue ($185.1M vs $123.8M, roughly 1.5× NATURES SUNSHINE PRODUCTS INC). Doximity, Inc. runs the higher net margin — 33.3% vs 3.3%, a 29.9% gap on every dollar of revenue. On growth, Doximity, Inc. posted the faster year-over-year revenue change (9.8% vs 4.7%). Over the past eight quarters, Doximity, Inc.'s revenue compounded faster (25.2% CAGR vs 5.6%).

Doximity is an online networking service for medical professionals. Launched in 2010, the platform offers its members curated medical news, telehealth tools, and case collaboration.

Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.

DOCS vs NATR — Head-to-Head

Bigger by revenue
DOCS
DOCS
1.5× larger
DOCS
$185.1M
$123.8M
NATR
Growing faster (revenue YoY)
DOCS
DOCS
+5.0% gap
DOCS
9.8%
4.7%
NATR
Higher net margin
DOCS
DOCS
29.9% more per $
DOCS
33.3%
3.3%
NATR
Faster 2-yr revenue CAGR
DOCS
DOCS
Annualised
DOCS
25.2%
5.6%
NATR

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
DOCS
DOCS
NATR
NATR
Revenue
$185.1M
$123.8M
Net Profit
$61.6M
$4.1M
Gross Margin
89.9%
72.5%
Operating Margin
38.9%
4.3%
Net Margin
33.3%
3.3%
Revenue YoY
9.8%
4.7%
Net Profit YoY
-18.1%
1379.4%
EPS (diluted)
$0.31
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DOCS
DOCS
NATR
NATR
Q4 25
$185.1M
$123.8M
Q3 25
$168.5M
$128.3M
Q2 25
$145.9M
$114.8M
Q1 25
$138.3M
$113.2M
Q4 24
$168.6M
$118.2M
Q3 24
$136.8M
$114.6M
Q2 24
$126.7M
$110.6M
Q1 24
$118.1M
$111.0M
Net Profit
DOCS
DOCS
NATR
NATR
Q4 25
$61.6M
$4.1M
Q3 25
$62.1M
$5.3M
Q2 25
$53.3M
$5.3M
Q1 25
$62.5M
$4.7M
Q4 24
$75.2M
$-321.0K
Q3 24
$44.2M
$4.3M
Q2 24
$41.4M
$1.3M
Q1 24
$40.6M
$2.3M
Gross Margin
DOCS
DOCS
NATR
NATR
Q4 25
89.9%
72.5%
Q3 25
90.3%
73.3%
Q2 25
89.2%
71.7%
Q1 25
89.5%
72.1%
Q4 24
91.6%
72.0%
Q3 24
90.0%
71.3%
Q2 24
89.3%
71.4%
Q1 24
89.4%
71.2%
Operating Margin
DOCS
DOCS
NATR
NATR
Q4 25
38.9%
4.3%
Q3 25
37.8%
7.0%
Q2 25
37.4%
3.7%
Q1 25
35.2%
5.4%
Q4 24
47.4%
3.8%
Q3 24
38.8%
4.6%
Q2 24
36.4%
5.1%
Q1 24
35.5%
4.2%
Net Margin
DOCS
DOCS
NATR
NATR
Q4 25
33.3%
3.3%
Q3 25
36.8%
4.2%
Q2 25
36.5%
4.6%
Q1 25
45.2%
4.2%
Q4 24
44.6%
-0.3%
Q3 24
32.3%
3.8%
Q2 24
32.7%
1.2%
Q1 24
34.4%
2.1%
EPS (diluted)
DOCS
DOCS
NATR
NATR
Q4 25
$0.31
$0.23
Q3 25
$0.31
$0.30
Q2 25
$0.27
$0.28
Q1 25
$0.31
$0.25
Q4 24
$0.37
$-0.02
Q3 24
$0.22
$0.23
Q2 24
$0.21
$0.07
Q1 24
$0.20
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DOCS
DOCS
NATR
NATR
Cash + ST InvestmentsLiquidity on hand
$64.8M
$93.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$979.3M
$161.6M
Total Assets
$1.2B
$261.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DOCS
DOCS
NATR
NATR
Q4 25
$64.8M
$93.9M
Q3 25
$169.2M
$95.6M
Q2 25
$137.3M
$81.3M
Q1 25
$209.6M
$86.5M
Q4 24
$165.3M
$84.7M
Q3 24
$184.2M
$78.7M
Q2 24
$111.4M
$68.7M
Q1 24
$96.8M
$77.8M
Total Debt
DOCS
DOCS
NATR
NATR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$2.1M
Stockholders' Equity
DOCS
DOCS
NATR
NATR
Q4 25
$979.3M
$161.6M
Q3 25
$1.1B
$166.7M
Q2 25
$1.0B
$163.7M
Q1 25
$1.1B
$167.1M
Q4 24
$1.0B
$161.0M
Q3 24
$961.2M
$162.6M
Q2 24
$913.6M
$156.4M
Q1 24
$901.4M
$159.7M
Total Assets
DOCS
DOCS
NATR
NATR
Q4 25
$1.2B
$261.1M
Q3 25
$1.3B
$264.8M
Q2 25
$1.2B
$254.9M
Q1 25
$1.3B
$252.7M
Q4 24
$1.2B
$240.9M
Q3 24
$1.1B
$245.3M
Q2 24
$1.1B
$235.8M
Q1 24
$1.1B
$247.3M
Debt / Equity
DOCS
DOCS
NATR
NATR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.01×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DOCS
DOCS
NATR
NATR
Operating Cash FlowLast quarter
$60.9M
$9.9M
Free Cash FlowOCF − Capex
$7.6M
FCF MarginFCF / Revenue
6.1%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
0.99×
2.41×
TTM Free Cash FlowTrailing 4 quarters
$28.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DOCS
DOCS
NATR
NATR
Q4 25
$60.9M
$9.9M
Q3 25
$93.9M
$18.5M
Q2 25
$62.1M
$4.3M
Q1 25
$98.5M
$2.6M
Q4 24
$65.2M
$12.2M
Q3 24
$68.3M
$9.6M
Q2 24
$41.2M
$1.3M
Q1 24
$63.9M
$2.2M
Free Cash Flow
DOCS
DOCS
NATR
NATR
Q4 25
$7.6M
Q3 25
$16.8M
Q2 25
$3.0M
Q1 25
$1.5M
Q4 24
$10.0M
Q3 24
$7.9M
Q2 24
$-2.0M
Q1 24
$-1.5M
FCF Margin
DOCS
DOCS
NATR
NATR
Q4 25
6.1%
Q3 25
13.1%
Q2 25
2.6%
Q1 25
1.3%
Q4 24
8.5%
Q3 24
6.9%
Q2 24
-1.9%
Q1 24
-1.4%
Capex Intensity
DOCS
DOCS
NATR
NATR
Q4 25
1.9%
Q3 25
1.3%
Q2 25
1.2%
Q1 25
0.0%
1.0%
Q4 24
0.0%
1.9%
Q3 24
0.0%
1.5%
Q2 24
0.0%
3.0%
Q1 24
0.0%
3.3%
Cash Conversion
DOCS
DOCS
NATR
NATR
Q4 25
0.99×
2.41×
Q3 25
1.51×
3.46×
Q2 25
1.16×
0.81×
Q1 25
1.58×
0.55×
Q4 24
0.87×
Q3 24
1.55×
2.21×
Q2 24
1.00×
0.97×
Q1 24
1.57×
0.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DOCS
DOCS

Subscription$175.4M95%
Service Other$9.7M5%

NATR
NATR

Other$68.1M55%
General Health Products$20.2M16%
Digestive Products$13.8M11%
Cardiovascular Products$12.1M10%
Personal Care Products$4.4M4%
Immunity Products$3.1M3%
Weight Management Products$2.1M2%

Related Comparisons